ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Alphamab Oncology clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 40 studies whose lead sponsor is Alphamab Oncology or one of 2 companies grouped under it. 16 are recruiting or about to start. Per ClinicalTrials.gov, last updated Sep 1, 2026.

Our grouping of 2 registry names, not the registry’s. See them and correct one ↓

Compare Alphamab Oncology with Merck and Akeso →

Pipeline: 8 programs

Each counted once: 8 with a study Alphamab Oncology leads registered in the last two years.

  • Phase 1
  • Phase 3

The 3 phase-3 programs — sign in to see them, free: with every program, filter by condition or phase and sort by first study or primary completion.

“Registry” is the highest phase of Alphamab Oncology’s own registered studies; Alphamab Oncology’s own pipeline document is not read yet. “Primary completion” is the earliest date still ahead among its live studies when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced. Programs are read from ClinicalTrials.gov, joined across names by rules and decisions each recorded with its evidence.

Licenses and deals

2 of Alphamab Oncology’s programs have a dated deal behind them: 2 licensed out. Each from the companies’ own releases and filings, linked; the registry does not record them.

Licensed out 2

What it is testing

The drugs Alphamab Oncology’s studies test, most open studies first — 6 drugs with a page of their own. Each count opens the studies in search.

Open now Not open: under way, finished or stopped

Coming up

7 of Alphamab Oncology’s studies under way reach primary completion within a year, 1 of them phase 3. The dates are the sponsor’s own estimates, which often move.

Phase 3 Other phases

  1. N’26
  2. 2D
  3. J’27
  4. F
  5. M
  6. A
  7. M
  8. 2J
  9. J
  10. 2A
  11. S
  12. 1O
  13. N

Add all 7 to your calendar (.ics) → With an account.

All 40 at a glance

Where each study is in its life, its phase and its countries. Each count opens them in search.

  • Open now1640%Not yet recruiting 9 · Recruiting 7
  • Under way, not recruiting38%
  • Completed923%
  • Stopped early718%
  • Status unknown or other513%

Phase

  • Phase 221
  • Phase 119
  • Phase 37

Where

  • China31
  • Australia4
  • United States1

Over the years

  1. 18
  2. 819
  3. 20
  4. 21
  5. 22
  6. 23
  7. 24
  8. 25
  9. 726

By the year each study started. 2026 so far in the lighter column.

Registry sponsor names on this page

Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.

Tell us about a missing company
No account needed. Please leave out personal details.

Each name exactly as ClinicalTrials.gov lists it, and how it relates to Alphamab Oncology.

  • Jiangsu Alphamab Biopharmaceuticals Co., Ltd
    Subsidiary
    Something wrong?
    What is wrong with this name?
    No account needed. Please leave out personal details.
    38 studies →
  • Alphamab (Australia) Co Pty Ltd.
    Regional office
    Something wrong?
    What is wrong with this name?
    No account needed. Please leave out personal details.
    2 studies →

Related but not counted here: Suzhou Alphamab Co., Ltd. (affiliate); Alphamab Jilin Co., Ltd. (affiliate).

Studies

Recruiting first, then most recently updated. Showing 40 of 40.